CELLINK AB (“CELLINK” or “The Company”) has been awarded project financing with partners. The company’s share of the project corresponds to an amount of EUR 350,000, of which the EU accounts for 100 percent of the cost.
CELLINK has been awarded project funding from the EU for the project “SilkFUSION – Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research” through “Horizon 2020 – Novel ideas for radically new technologies “. Together with 6 partners, CELLINK has received funding for the project at 100 percent of the project’s total estimated cost: approximately EUR 3 million. The project is scheduled for 48 months and the Company’s share of the project corresponds to an amount of EUR 350,000. The company does not incur any costs for the project. CELLINK’s counter performance is entirely within the lines of the company’s regular operations. The company is for the project developing new Bioink for the specific application.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: +46 73 267 00 00 Phone: +46 70 991 86 04
E-mail: eg@cellink.com E-mail: gd@cellink.com
About CELLINK
CELLINK has created one of the world’s first universal Bioinks, today used by many of the world’s most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK’s universal Bioink shows excellent results and can be used in both CELLINK’s proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Mangold Fondkommission AB, tel: +46 (0) 8 5030 1550, is the Company’s Certified Adviser.
This release was sent by Cision
